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ABSTRACT
Obesity, favored by the modern lifestyle, acquired epidemic proportions nowadays. Obesity has been associated with various major causes of 
death and morbidity including malignant neoplasms. This increased prevalence has been accompanied by a worldwide increase in cutaneous 
melanoma incidence rates during the last decades. Obesity involvement in melanoma aetiology has been recognized, but the implicated 
mechanisms remain unclear. In the present study, we address this relationship and investigate the influence of adipocytes secretome on 
B16-F10 and MeWo melanoma cell lines. Using the 3T3-L1 adipocyte cell line, as well as ex vivo subcutaneous (SAT) and visceral (VAT) 
adipose tissue conditioned medium, we were able to show that adipocyte-released factors play a dual role in increasing melanoma cell overall 
survival, both by enhancing proliferation and decreasing apoptosis. B16-F10 cell migration and cell–cell and cell–matrix adhesion capacity 
were predominantly enhanced in the presence of SAT and VAT released factors. Melanocytes morphology and melanin content were also 
altered by exposure to adipocyte conditioned medium disclosing a more dedifferentiated phenotype of melanocytes. In addition, exposure to 
adipocyte-secreted molecules induced melanocytes to rearrange, on 3D cultures, into vessel-like structures, and generate characteristic 
vasculogenic mimicry patterns. These findings are corroborated by the released factors profile of 3T3-L1, SAT, and VAT assessed by 
microarrays, and led us to highlight the mechanisms by which adipose secretome from sub-cutaneous or visceral depots promote melanoma 
progression.
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Obesity prevalence has significantly increased worldwide[Rubenstein, 2005], leading to a public health concern and
branded as “the modern epidemic” [Haffner and Taegtmeyer, 2003;
Rubenstein, 2005]. The prevalence of obesity in Europe has increased
by approximately 30% over the past 10 years and this phenomenon
is corroborated by data from several other countries [Bergh€ofer et al.,
2008]. It has long been recognized that excess adipose tissue (AT)
increases the risk of cardiovascular disease, type 2 diabetes and
metabolic syndrome [Haffner and Taegtmeyer, 2003; Rubenstein,
2005], but only in the past few decades it became widely accepted
that augmented body adiposity is a risk factor for several types of
malignancies [Taubes, 2012; Vucenik and Stains, 2012]. Addition-
ally, obesity can lead to worsened prognosis, poorer treatment
outcome, and increased cancer-related deaths [Parekh et al., 2012].
Cutaneous melanoma incidence rates have increased in the last
decades worldwide from 3% to 7% annually [Tuong et al., 2012].
Abbreviations used: 
AT, adipose tissue; 
CM, conditioned medium; 
DMEM, Dulbecco0s modified eagle0s medium; 
FBS, foetal bovine serum; 
FGF, fibroblast growth factor; 
HGF, hepatocyte growth factor; 
HMEC-1, human microvascular endothelial cells; 
IGF, insulin-like growth factor; 
IGFBP, insulin-like growth factor binding protein; 
IL, interleukin; 
LIF, leukaemia inhibitory factor; 
MCP-1, monocyte chemotactic protein 1; 
PAI-1, plasminogen activator inhibitor-1; 
PBS, phosphate buffered saline; 
RBP-4, Retinol binding protein-4; 
SAT, subcutaneous adipose tissue; 
SEM, standard error of the mean; 
TIMP, tissue inhibitor of metalloproteinases; 
VAT, visceral adipose tissue; 
VEGF, vascular endothelial growth factor.
*Correspondence to: Raquel Soares, Departamento de Bioquımica, Faculdade de Medicina da Universidade do Porto,
Al. Prof. Hern^ani Monteiro, 4200-319 Porto, Portugal. E-mail: raqsoa@med.up.pt
These statistics suggest a doubling of rates every 10–20 years [Marks,
2000; Garbe and Leiter, 2009], raising melanoma to the most rapidly
increasing cancer in Caucasians [Garbe and Leiter, 2009]. Several
reports showed positive associations between increased body fat and
the risk of cutaneous melanoma later in life [Dennis et al., 2008;
Morpurgo et al., 2012; Nagel et al., 2012; Sergentanis et al., 2013],
suggesting that the increasing incidence of melanoma may be
related to the enlarged obesity prevalence.
In vivo adiposity-related stimulation of melanoma growth has
been demonstrated [Brandon et al., 2009; Pandey et al., 2012;
Wagner et al., 2012; Jung et al., 2015]. Tumour-associated
macrophages [Wagner et al., 2012; Jung et al., 2015] and endothelial
cells [Jung et al., 2015] have been pointed out as possible mediators
in the growth-promoter effect of adipose tissue towards melanomas.
In fact, tumour stroma comprises many different cell types,
including fibroblasts, adipocytes, immune, and endothelial cells
that, along with the extracellular matrix, are key players in cancer
development and progression [Brychtova et al., 2011; Friedl and
Alexander, 2011]. However, we hypothesize that adiposity might
also exert a direct effect over melanocytes without the involvement
of stromal cells in a paracrine or endocrine manner. Herein, we
explored the biological role of adipocytes secretome in B16-F10 and
MeWo melanoma cell survival and plasticity.
MATERIALS AND METHODS
CELL CULTURE AND IN VITRO TREATMENTS
The mouse melanoma B16-F10 cells exhibit in vitro a mixed
morphology of spindle-shaped and epithelial-like cells. It was
originally isolated from melanoma of the C57BL/6J mouse strain.
B16-F10 is a metastatic variant of B16melanomas with high tropism
for lung invasion.
The human melanoma cell line MeWo was originally derived and
established in culture froma lymphnodemetastasis froma 78-year-old
male patient.MeWo is also ametastatic cell line. Similarly toB16-F10 it
also resembles moderate lung invasion ability.
B16-F10 murine melanoma cell line (ATCC CRL-6475), MeWo
human melanoma cells (ATCC HTB-65), and 3T3-L1 pre-adipocytes
(ATCC CL-173) were maintained in Dulbecco0s modified eagle0s
medium (DMEM; Sigma–Aldrich), Human dermal microvascular
endothelial cells (HMEC-1, ATTC CRL-3243) were cultured in RPMI-
1640 (Sigma–Aldrich) containing 10–ng/mL epidermal growth
factor (BD Biosciences) and 1mg/mL cortisone (Sigma–Aldrich).
Both media formulations were supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Sigma–Aldrich), 1% penicil-
lin/streptomycin/amphotericin B (Sigma–Aldrich). Cells were grown
at 37°C under a humidified 5% CO2 atmosphere. Cells were serum-
deprived during 16 h before incubation with each treatment for
every experiment. Unless otherwise specified, all treatments and
controls were carried out in serum-free conditions.
ADIPOCYTE DIFFERENTIATION AND CONDITIONED MEDIUM
COLLECTION
3T3-L1 pre-adipocytes were harvested and allowed to reach
confluence. After 2 days (day 0), the differentiation was initiated
by addition of a hormonal mixture composed of 2mM insulin
(Sigma–Aldrich), 1mM dexamethasone (Sigma–Aldrich) and
0.25mM isobutylmethylxanthine (Fluka) in complete medium.
Three days later (day 3), the induction medium was replaced by
complete medium supplemented with insulin only. At day 7, cultures
with a differentiation yield higher than 80% were washed with
phosphate buffered saline (PBS) and incubated in serum-free DMEM.
After 24–h (day 8), the conditionedmedium (CM)was harvested from
the adipocytes cultures, spun for 5min at 300g and the supernatant
was stored at 80°C for the subsequent treatments.
ADIPOSE TISSUE ORGAN CULTURE
Fragments (8–10mg) from visceral adipose tissue (VAT) and
subcutaneous adipose tissue (SAT) depots were collected from
8-week-male C57BL/6J mice. The fragments were then washed with
1% penicillin/streptomycin/amphotericin B (Sigma–Aldrich) in PBS
and cultured afterwards in 1mL of DMEM supplemented with 10%
FBS. The fragments were serum-deprived and 24–h later the CM
harvested and centrifuged at 300g for 5min.
MOUSE ADIPOKINE ARRAY ANALYSIS
Mouse adipokine antibody arrays (-# ARY-013; R&D systems) were
performed using 1mL of 3T3-L1, SAT, and VAT CM and following
the manufacturer0s protocol. The pixel density of each spot was
calculated with the microarray profiler plugin of the Image J
software (NIH). The relative adipokine levels were calculated upon
normalization with the adipokine levels of B16-F10 CM.
CELL VIABILITY ASSAY
To measure B16-F10 metabolic activity, after a 24 h incubation of
1 104 cells/mL with the different treatments, 20mL of the MTS
reagent, from CellTiter 96 Aqueous assay (Promega), was added into
each 96-plate well followed by a 3 h incubation period. Color
development was determined by measuring absorbance at 490 nm.
APOPTOSIS ASSAY
Terminal deoxynucleotidyl transferase-mediated deoxyuridine tri-
phosphate nick-end labelling (TUNEL) assay was performed in
B16-F10 cells (1 104 cells/mL), after 24 h incubation with the
different treatments using the In Situ Cell Death Detection Kit (Roche
Diagnostics) following the manufacturers protocol. Nuclei were
counter-stained with DAPI (Roche Diagnostics) and immunofluo-
rescence was visualized under a fluorescence microscope (Nikon).
The percentage of TUNEL-positive cells was evaluated by counting
the cells stained with TUNEL divided by the total number of DAPI-
stained nuclei at a 200 magnification field. One thousand nuclei
were evaluated. The results are presented asmean standard error of
the mean (SEM).
BRDU PROLIFERATION ASSAY
B16-F10 cells (1 104 cells/mL) were cultured with standard
treatments in serum-free conditions for 20 h. Then bromodeoxyur-
idine (BrdU; Roche Diagnostics), at a final concentration of 0.01mM,
was added to each well for 4 h. The detection was performed using
the colorimetric Cell Proliferation ELISA, BrdU (Roche Diagnostics),
according to the manufacturer0s instructions.
CELL SPREADING AND ADHESION DETERMINATION
To determine cell spreading and adhesion [Humphries, 2001],
B16-F10 cells were re-suspended in the different treatments at afinal
concentration of 5 104 cells/mL, seeded in a 24-well microplate
and allowed to adhere and spread for 3 h and then washed with PBS
to remove non-adherent cells. Fixationwas performedwith 4% (w/v)
p-formaldehyde in PBS. Afterwards, 200mL of crystal violet 0.1%
(w/v) was added to each well for 20min and later washed with H2O.
To evaluate the morphologic parameters (cell area, sphericity, size,
and perimeter), 1,000 cells were analyzed by CellProfiler software
(Broad Institute) on photographs of random fields, for each
treatment, captured under an inverted microscope (Nikon) at a
200magnification. To determine cell adhesion, the above protocol
was reproduced but only allowing cells to adhere for 30min.
Afterwards, crystal violet dye was solubilized in 100mL 10% (v/v)
acetic acid (Fluka) and the absorbance measured at 570 nm using a
plate reader.
ADHESION TO ENDOTHELIUM EVALUATION
HMEC-1 cells were cultured in a 24-well microplate with glass
coverslips and allowed to reach confluence. Media was aspirated and
the monolayers were washed with PBS. Afterwards, 1 105 cells/mL
B16-F10 cells, in the different treatments were added to the wells for
30min. To remove non-adherent cells, the wells were washed with
PBS. Fixation was performed with 4% (w/v) p-formaldehyde for
10min. Coverslips were then stainedwith Giemsa0s stain, thoroughly
washed in Sorensen0s phosphate buffer and mounted on a
microscope slide. Using a light microscope (Nikon) the number of
cells adherent to the endothelial monolayer were counted in five
random fields.
MELANIN CONTENT DETERMINATION
B16-F10 cells (5 105 cells/mL), were incubated with the different
treatments for 24 h. Following detachment with 0.5% trypsin, cell
density was assessed on a haemocytometer. After 300g centrifuga-
tion for 10min, the pellet was washed twice with PBS and the
melanin was solubilized in 1.0mL of 1M NaOH (Panreac) containing
10% (v/v) dimethyl sulfoxide (Merck). Next, the absorbance at
475 nm was recorded. Results represent the mean absorbance
(SEM) of 1 106 cells.
TRANSWELL MIGRATION
Migration capacity was quantified on 24-well plates with 8mm-pore
transwell inserts (BD Biosciences). B16-F10 cells (5 104 cells/mL)
were harvested on inserts in serum-free medium and placed on wells
containing the standard treatments plus 10% FBS for 24 h.
Membranes were then stained with crystal violet 0.1% (w/v) and
visualized under a light microscope (Nikon). Five random fields of
each membrane were counted on the microscope (Nikon) at a 100
magnification.
INJURY ASSAY
To perform the injury assay, melanoma cells at confluence were
scrapped from the culture dish using a pipette tip, which left a void
space. Cells were then incubated for 24 h following the standard
treatments. After this period, damage recovery was then visualized
and photographed under an inverted microscope (Nikon) at a 200
magnification. The wound closure was determined by measuring
the wound area and by subtracting this value from the initial void
space (CellProfiler software; Broad Institute). Shown are the means
values (SEM) of nine measurements for each time point and
condition.
MATRIGEL CULTURES
To performMatrigel cultures, 24-well plates were coated with 250mL
per well of Matrigel Basement Membrane Matrix (Corning). After-
wards, B16-F10 (5 104 cells/mL) or MeWo (20 104 cells/mL)
melanocytes harvested in the respective treatments were fed on top
of the Matrigel layer. Cell growth was then monitored and photo-
graphed under an inverted microscope (Nikon) at a 200magnifica-
tion for 24h.
SOFT-AGAR COLONY FORMATION
The bottom of each 12-well plate was coated with 2mL of 0.5%
agarose and DMEM 2X. After polymerization the wells were fed with
5 103 B16-F10 cells in 2mL of 0.2% agar and DMEM 2X. The
medium was changed every 2–3 days. After 15 days, the wells were
stainedwith 0.01% crystal violet and photographed. The number and
area of the colonies was assessed with ImageJ software (NIH).
HANGING-DROP CELL CULTURES
Generation of melanoma spheroids was conducted as previously
described [Foty, 2011]. Briefly, 2.5 106 B16-F10 or MeWo cells/mL
were collected in the respective treatments and pippeted to the lid of
a 60mm non-adhesive petri dish leaving 10mL drops onto the
bottom of the lid. The lids were inverted, placed on top of the PBS-
filled bottom chamber of the dish and incubated for 3 days.
STATISTICAL ANALYSIS
Results are expressed as mean SEM. Data were analyzed with
GraphPad Prism 6.0 (GraphPad Software Inc.). Differences between
samples and parameters among two experimental groups were
evaluated by Student0s t-test. When three or more conditions were
evaluated, statistical analysis was conducted through one-way
ANOVA with Sidak post-hoc test. Significance was set at P< 0.05.
RESULTS
3T3-L1 SECRETOME INCREASES MELANOCYTES SURVIVAL,
PROLIFERATION AND MELANIN CONTENT, AND DECREASES
APOPTOSIS
3T3-L1 preadipocytes are a commercially available cell line for
studying adipogenesis [Green and Kehinde, 1975; Poulos et al.,
2010]. Their differentiation, in culture, intomature adipocytes is well
widespread and can be achieved by established protocols. We used
CM from fully differentiated 3T3-L1 cells to explore the potential
effects of adipocytes secretome over malignant melanoma B16-F10
cells viability, proliferation, and apoptosis.
We first analyzed the effects of this conditioned medium in
melanoma cells viability by the MTS assay. After a 24 h exposure
to adipocyte CM, melanoma cells showed a 48% increase in their
metabolic activity (Fig. 1A). We found as well that the fraction of
proliferating B16-F10 cells was significantly increased, as shown
by the higher BrdU incorporation, in the presence of these
adipocyte-released factors (Fig. 1B). The effect of 3T3-L1
secretome on apoptosis was examined using TUNEL analysis.
Concomitantly, 3T3-L1 CM medium decreased B16-F10 pro-
grammed cell death by approximately 50% (Fig. 1C). These effects
were further accompanied by a significant reduction in melanin
content per cell (Fig. 1D).
ADIPOCYTE SECRETOME PROFILE CHARACTERIZATION
The previous findings imply that adipocytes released factors
stimulate melanoma cell viability and aggressiveness. Therefore,
we then assessed the secretion profile of adipocytes to further
elucidate the involvement of adipose tissue in melanoma behavior
(see Supplemental data). Given the well-established distinct
biological and metabolic roles of sub-cutaneous (SAT) and visceral
(VAT) adipose tissue, microarray assay was performed not only in
3T3-L1 cells, but also in organ cultures of SAT and VAT fragments.
As illustrated in Figure 2, the secretion patterns of numerous
growth-factors, adipokines, cytokines, and angiogenesis-related
molecules are different among the different CM. Greater levels of
vascular endothelial growth factor (VEGF) and endocan were
found in SAT and VAT CM, whereas tissue inhibitor of
metalloproteinases-1 (TIMP-1) levels were significantly reduced
in these two CM (Fig. 2A). On the other hand, 3T3-L1 CM exhibited
higher levels of VEGF, TIMP-1, and endocan than B16-F10-CM
(Fig. 2A). The levels of the interleukin (IL) family of cytokines:
IL-6, IL-11, and leukaemia inhibitory factor (LIF) were also
significantly overexpressed within SAT and VAT, although no
substantial differences were found in the 3T3-L1 CM (Fig. 2B).
Nonetheless, monocyte chemotactic protein 1 (MCP-1) and
plasminogen activator inhibitor-1 (PAI-1) expression was upre-
gulated in every CM (Fig. 2B). Adipose tissue hormones were also
identified. Resistin and leptin relative expression levels were
higher in 3T3-L1, SAT, and VAT CM. In addition, Retinol binding
protein-4 (RBP-4) was significantly released in SAT and VAT, but
not in 3T3-L1 CM. Interestingly enough, a significant reduction in
adiponectin levels was observed in all CM (Fig. 2C). The levels of
several growth factors involved both in metabolism and in cell
behavior were also analyzed. VAT CM revealed the higher
expression of fibroblast growth factor (FGF)-21, insulin-like
growth factor binding protein (IGFBP)-5, whereas hepatocyte
growth factor (HGF), insulin-like growth factor(IGF)-I, IGFBP-2,
IGFBP-3, and IGFBP-6 levels were significantly higher in SAT than
VAT CM (Fig. 2D).
Fig. 1. 3T3-L1 secretome increases melanoma cell survival. B16-F10 cells
were incubated with CM from differentiated 3T3-L1 cells cultures (3T3-L1 CM)
or untreated (Control) for 24 h. (A) An increase in the percentage of viable
melanoma cells was observed when compared with control. Results represent
the percentage of viable cells normalized by the absorbance of control. (B) The
number of proliferating cells, incorporating BrdU, increased in the presence
3T3-L1 CM. Results represent the percentage of proliferating cells normalized
over the absorbance of control. (C) A significant decrease in the percentage of
apoptotic cells was observed when melanocytes were treated with 3T3-L1 CM.
Results represent the percentage of apoptotic cells evaluated by the ratios of
TUNEL-positive cells versus total DAPI-counterstained nuclei. (D) The melanin
content per cell was significantly decreased whenmelanocytes were cultured in
presence of 3T3-L1 CM. Melanin concentration was calculated by
determination of OD 475. Results represent the absorbance of 1 106 cells.
(P< 0.05 vs. Control; n¼ 9).
Fig. 2. Secretion profiles of 3T3-L1 cells and subcutaneous and visceral AT
organ cultures. (A) Both SAT and VAT CM exhibit greater levels of VEGF and
endocan with a concomitant reduction in the expression of TIMP-1. (B) Distinct
relative levels of IL-6, IL-11, and LIF were found among SAT and VAT CM (C)
Adipokines leptin and resistin are overexpressed in all CM, whereas diponectin
levels are significantly reduced (D) Numerous cellular growth factors were
present at considerably higher concentrations in both VAT and SAT CM
(P< 0.05 vs. Control; #P<0.05 SAT CM vs. VAT CM; n¼ 2).
SAT AND VAT DISTINCTIVELY MODULATEMELANOCYTE MIGRATION
AND CELL SPREADING
According to the previous secretome profile, TIMP-1, an inhibitor of
extracellular matrix degradation was significantly decreased,
whereas several inflammatory cytokines and angiogenic growth
factors were upregulated particularly in SAT and VAT. These
findings led us to evaluate the influence of CM in melanocytes
motility. We first analyzed whether 3T3-L1 CM mechanically
induced a wound to B16-F10 confluent cultures by injury assay. As
illustrated in Figure 3A, the resulting void area was promptly
occupied bymelanocytes upon 3T3-L1 CM incubation in comparison
to untreated B16-F10 cultures. Following a 24 h incubation with CM,
the migrated distance is almost twice the distance of the control
treatment as seen by the microscopic examination of the wounds
(Fig. 3B). We then examined the effect of SAT and VAT fat depots
secretome in B16-F10 cells motility. In the double-chamber
migration assay, the number of migrating cells following a
chemotactic gradient was significantly enhanced in every treatment
as compared to untreated B16-F10 cultures (Fig. 3C). However, SAT
CM exerted this effect into a much larger extent. Cell spreading
evaluation revealed that VAT and 3T3-L1 secretedmolecules, but not
SAT, induced spreading dynamic of B16-F10 cells (Fig. 3D). In
addition, VAT CM-treated B16-F10 cells exhibited significantly
higher areas and perimeter, whereas a smaller number of round
shaped cells were observed. In contrast, SAT secreted factors did not
significantly alter B16-F10 spread plasticity (Fig. 3E). These findings
highlight a distinct paracrine role of AT depots regarding B16-F10
locomotive behavior: although SAT-released factors boost mela-
noma cell chemotaxis, VAT CM signalling enhance cell morpholog-
ical plasticity and haptotactic spreading.
AT SECRETOME MODULATES MELANOMA CELLS ADHESION AND
TUMORIGENESIS
Decreased cell–cell adhesion and anchorage-independent growth
are prominent features necessary for successful metastization
[Chiang and Massague, 2008; Friedl and Alexander, 2011].
Therefore, we evaluated the adhesion of CM-treated B16-F10 cells
to standard cell culture plates. Interestingly, B16-F10 cells adhesion
was significantly increased after incubation with every CM, being
higher upon VAT medium exposure (Fig. 4A).
Identical findings were observed in B16-F10 cells adhesion to
endothelial cells (Fig. 4C). The number of B16-F10 cells adherent to
Fig. 3. In vitro motility, migration and spreading analysis of B16-F10 melanocytes. (A) A rapid B16-F10 cell migration was observed after incubation with 3T3-L1 CM in
comparison to untreated (Control) for 24 h. Cell cultures were visualized under an inverted microscope at a 200magnification. (B) When exposed to 3T3-L1 CM, melanocytes
rapidly occupied the injury-created void area. The wound closure was determined by measuring cultures void area and by subtracting it from the initial area of the wound. Bars
show themeans values (SEM) of ninemeasurements for each time point/condition. (C) The effects of AT secretome on cell migration were quantified in a double-chamber assay
using FBS as a chemoattractant. The number of cells that invaded the membrane was significantly higher when treated with 3T3-L1, and particularly with SAT and VAT CM.Mean
values (SEM) of three independent measurements are shown (P< 0.05 vs. Control; #P< 0.05 SAT CM vs. VAT CM; n¼ 3). (D) B16-F10 cells were allowed to adhere and spread
for 3 h in the standard treatments. Representative images of crystal-violet stainedmelanoma cells are shown (200X). (E)Morphologic analysis of B16-F10 cells revealed that VAT
and 3T3-L1 CM significantly enhanced cell spreading. Bars are the means values SEM, represented as percentage of Control, of 1,000 evaluated cells (P< 0.05 vs. Control;
n¼ 9).
HMEC-1 monolayers was significantly enhanced both after SAT and
VAT CM treatments as compared to untreated cells or to cells treated
with 3T3-L1 CM (Fig. 4B), being the highest increase found upon
VAT CM incubation. These findings confirm that VAT improves
B16-F10 adhesive properties. Conversely, in the soft-agar clono-
genic assay, SAT soluble factors promoted the anchorage-indepen-
dent proliferation of B16-F10 cells upon culture in non-adherent
conditions (Fig. 4D and E), whereas exposure to VAT CM did not
exert any effect. SAT released factors increased the number of
colonies formed, but not in a statistically significant manner
(Fig. 4F). These results further emphasize the divergent roles of SAT
and VAT towards melanocytes malignancy.
ADIPOCYTES SECRETED FACTORS INDUCE MALIGNANT
MELANOCYTES VASCULOGENIC MIMICRY
Given that malignant melanomas are highly vascularized tumours
[Pirraco et al., 2010; Chung and Mahalingam, 2014] and metastatic
melanoma cells actively participate in tumour vascularization
[Hendrix et al., 2003; Chung and Mahalingam, 2014], we next
addressed whether CM from 3T3-L1 adipocytes prompted B16-F10
melanoma cells toward vasculogenic mimicry.
In comparison to untreated cells, 3T3-L1 CM-treated B16 cells
rapidly assembled into capillary-like structures when cultured in
Matrigel basement matrix (Fig. 5A). To further confirm the three-
dimensional growth and spatial arrangement of the melanoma cells,
B16-F10 cells were cultured in hanging-drops for 72h. Microscopic
observation of the generated spheroids upon incubation with 3T3-L1
CM revealed the formation of large and diffused aggregates of
B16-F10 cells, whereas in the control treatment, a spherical and
compact mass of melanocytes was observed (Fig. 5B). Next, we used
MeWo cell line to additionally examine the vasculogenic mimicry
inducer effects of 3T3-L1 CM in human melanoma cells. MeWo cells,
when cultured on top of Matrigel and in the presence of 3T3-L1 CM
displayed the same vessel-like rearrangement already observed for
B16-F10 melanocytes (Fig. 5A). MeWo spheroids further revealed a
loophole growth pattern when exposed to 3T3-L1-released factors
(Fig. 5B). Altogether, these findings regarding cell–cell adhesion and
reorganization intovessel-like structures formationprovideadditional
Fig. 4. Melanoma cells adhesion and anchorage-independent growth were increased after incubation with AT CM. (A) Adhesion to culture plates for 30min; (B) Adhesion to
HMEC-1 monolayers for 30min. VAT-released factors were prominent in enhancing melanocytes adhesive potential both to culture plates and endothelial cells. Results are
expressed as percentage of Control (SEM). (C) Representative images (800X) of Giemsa stained slides showing B16-F10 cells (dark blue) adherent to HMEC-1 monolayers
(pink). (D) Evaluation of anchorage-independent proliferation of B16-F10melanocytes was conducted by soft-agar colony formation assay. (E) The number of colonies formed
was significantly higher in both 3T3-L1 and SAT CM treatments but not in VAT CM. (F) Mean B16-F10 colony area was significantly increased after 3T3-L1 CM incubation, but
not after VAT or SAT CM treatment. Bars represent means SEM (P< 0.05 vs. Control; #P< 0.05 SAT CM vs. VAT CM; n¼ 3–9).
support and reinforce the deleterious effects of fat-secreted molecules 
on melanoma tumour progression.
DISCUSSION
Emerging evidence indicates that systemic factors, including
inflammatory, angiogenic or metabolic markers, significantly
influence tumour behavior [Hanahan and Weinberg, 2011].
The current study reveals that adipocyte-released factors increase
B16-F10 melanoma cells viability, proliferation, and reduces
apoptosis and melanin content. Exposure to adipose tissue CM of
these cells further resulted in increased motility, enhancing the
capacity to migrate and spread. These findings were accompanied by
an augmented adhesion capacity, in particularly to endothelial cells,
and anchorage-independent proliferation as assessed by soft agar
assays.We further identified the factors that are released by adipocyte
cells of different depots, and revealed that several pro-inflammatory
factors (IL-6, IL-11, LIF, and PAI-1), metabolic markers (IGFBPs,
FGF-21), angiogenic growth factors (endocan, HGF, VEGF IGF-I), and
hormones (leptin, resistin, RBP-4) were secreted to the medium into a
high extent, whereas TIMP-1, an inhibitor of ECM degradation, and
adiponectin were significantly downregulated.
Adipose tissue is no longer considered amere lipid store depot, but
also an inflammatory and endocrine organ [Monteiro, 2009;
MendonSca and Soares, 2015]. Accordingly, obesity provides a
chronic low grade inflammatory condition, further potentiated by
the presence of hormone cues and cytokines, which are strongly
associated with disease. Therefore, the presence of high amounts of
pro-inflammatory cytokines and hormones in adipocyte CM is
expected. Remarkably, the majority of these factors are known to
play a role in cell proliferation, apoptosis, migration, and
invasiveness, as well as adhesion capacity. Recently, it has been
reported that both leptin and resistin, two adipocyte-released
hormones, were able to stimulate melanoma cell growth and
proliferation through Akt and fatty acid synthase modulation [Malvi
et al., 2015]. In addition to these hormones, FGF-21, a metabolic
regulator also increases cell proliferation in vitro and increased
tumorigenesis and invasive potential in vivo [Osawa et al., 2009].
Likewise, FGF and IL-6 are known to be produced by melanoma cells
and stimulate proliferation in a autocrine manner, although other
paracrine growth factors (HGF, IGF-I, and VEGF) modulate the
microenvironment and potentiate tumor growth and invasion
[Lazar-Molnar et al., 2000; Hoashi et al., 2001]. We have found
that adipose tissues CM have significant higher levels of the above
growth factors, reinforcing our findings concerning the effect of CM
from the distinct adipose tissue depots studied in augmenting
B16-F10 cell proliferation, migration, ability to invade, and
decreasing apoptosis.
Along with the progression of melanoma, malignant melanocytes
dedifferentiate losing most of their epithelial characteristics through
a process similar to epithelial-mesenchymal transition [Fenouille
et al., 2012], leading thus to more aggressive phenotypes [Thiery,
2002]. Melanogenesis is an inherent process in melanocytes.
Melanocytes respond to the inflammatory cytokines, namely IL-6,
with a dose-dependent inhibition of melanogenesis [Kotobuki et al.,
2012]. Nevertheless, whenever these cells exhibit a more malignant
phenotype, melanocytes decrease melanin synthesis [Jimbow et al.,
1993]. Our findings show that when treated with CM from
adipocytes, the melanin content per B16-F10 melanocyte was
significantly reduced, further enlightening the growth-promoter and
dedifferentiation paracrine effects of adipocytes.
Furthermore, active locomotion of tumour cells is fundamental to
malignant invasive andmetastatic capacity [Zhao et al., 2001; Fidler,
2003; Friedl and Wolf, 2003]. By crossing tissue stroma and the
vascular bed, tumour cells interact with both extracellular matrix
and soluble tropic factors. Our findings showed that chemotactic
migration of B16-F10 cells was enhanced upon exposure to SAT-
released factors although cell spreading and haptotactic migration of
tumour cells were positively modulated by visceral-fat secretome.
Intercellular adhesion is reduced in many aggressive tumours
[Chiang and Massague, 2008], allowing cells to detach from the
primary lesion and metastasize to distant organs. Again, we found
discrete effects among subcutaneous and visceral fat depots on
B16-F10 adhesive properties. In fact, several biological, metabolic,
and secretory differences distinguish intra-abdominal visceral-
adipocytes from peripheral subcutaneous adipose tissue [Ibrahim,
2010; Ali et al., 2013]. In agreement, our results unveiled distinct
effects of SAT and VAT upon melanocytes aggressiveness. SAT CM
enhances B16-F10 locomotion and anchorage-independent prolif-
eration. In turn, VAT prominently improves melanocytes cell-
substratum adhesion. Despite the higher release of visceral-fat
Fig. 5. Vasculogenic mimicry by melanoma cells was stimulated by AT CM. (A)
B16-F10 and MeWo cells were cultured on top of Matrigel layers. Upon
treatment with 3T3-L1 CM, melanocytes acquired a vessel-like tubular
phenotype. Images were captured under an inverted microscope (200) at 12
and 24 h post treatment. (B) Microscopic examination of B16-F10 and MeWo
spheroids in hanging-drop cultures. The presence of 3T3-L1 secreted factors
inhibited the formation of a compact spheroid cellular mass. Shown are
representative light-microscopy photographs (80) of the spheroids.
pro-inflammatory cytokines [Ibrahim, 2010], subcutaneous fat
depots, which are located close to melanoma lesions, influence the
malignant transformation of melanocytes. Nevertheless, our micro-
array assay revealed that the secretome profile of SAT and VAT is
significantly different regarding some of the inflammatory,
hormonal, and metabolic molecules addressed. TIMP-1 and IGF-I
are chemotactic agents for human melanoma cells that mediate
motility [Hoashi et al., 2001; Neudauer and McCarthy, 2003]. IGF-I
was significantly higher in SAT CM although TIMP-1 was under
expressed in the adipose tissues CM. PAI-1 is also known tomodulate
cell adhesive properties and its overexpression is correlated with the
metastatic capacity of melanomas [Quax et al., 1991]. Antagonisti-
cally, IGFBPs inhibit melanoma migratory and invasive behavior,
and induce melanocytic differentiation [Naspi et al., 2014] counter-
balancing the IGF-I effects and most likely contribute to the discrete
differences observed between subcutaneous and visceral CM. The
effect of the different AT depot secretome in tumour cells behavior is
beyond the scope of this study, however, our results reinforce the
need for additional molecular studies to investigate how SAT and
VAT affect tumour progression.
Accumulating data point out mechanisms associating obesity to
melanoma [Dennis et al., 2008; Brandon et al., 2009; Meeran et al.,
2009; Morpurgo et al., 2012; Pandey et al., 2012; Chen et al., 2013].
Recent reports unveiled the involvement of high-fat diet-induced
increased cytokines and angiogenic factors in the crosstalk between
tumour cells and macrophages [Costa et al., 2007; Wagner et al.,
2012; Jung et al., 2015; MendonSca et al., 2015]. Recruitment of the
immune system cells, which release factors that enhance tumour
plasticity and the maintenance of stromal microenvironment, has
already been described for other malignancies [Fridman et al., 2012;
Hanahan and Coussens, 2012]. In contrast, our in vitro results
disclose a direct effect of adiposity on melanoma cells, without the
influence of either tumour-associated cell-mediated immunity or
endothelium.
Vascularization plays a central role in tumour development and
progression. Besides angiogenesis, vasculogenic mimicry provides
an alternative, angiogenic-independent tumour microcirculation
[Maniotis et al., 1999; Hendrix et al., 2003; Ribatti et al., 2013].
Melanoma cell-lined vascular networks sustain a redundant blood
supply required for both growth and metastasis [Maniotis et al.,
1999; Ribatti et al., 2013]. The presence of these functional vascular
channels by the tumour itself is a predictor of poor prognosis in
human melanoma patients [Thies et al., 2001; Cao et al., 2013] and
might circumvent the effectiveness of anti-vascular drugs and anti-
angiogenic therapies [Loges et al., 2010]. Fully differentiated 3T3-L1
adipocytes CM were able to induce malignant melanocytes to
rearrange on Matrigel cultures into vessel-like structures typically
reported for endothelial cells [Kleinman and Martin, 2005].
Moreover, microscopic inspection of B16-F10 and MeWo spheroids,
obtained by hanging-drop cultures, revealed the same pattern of
vasculogenic mimicry observed in cultures of human melanoma cell
lines [Maniotis et al., 1999; van der Schaft et al., 2004]. Data
confirmingmelanoma angiogenesis stimulation by AT tropic factors
has recently been highlighted [Wagner et al., 2012; Jung et al., 2015].
However, we report for the first time supporting evidence endorsing
the potential adipocyte secretome inducer effects of tumour
vasculogenic mimicry. Accordingly, several angiogenic growth
factors were significantly higher in CM, including HGF and VEGF.
HGF was involved in vascular mimicry of hepatocellular carcinoma
[Lirdprapamongkol et al., 2012]. Additionally, VEGF signalling was
found to be involved in vascular mimicry through activation of
VEGFR1 expression in melanoma cells [Frank et al., 2011],
explaining the increased capacity of melanoma cells to form
vasculogenic structures after treatment with adipocyte CM.
Endocan, in turn, is a new tumour invasion and angiogenic marker,
being overexpressed in tumour vessels [Matano et al., 2014]. The fact
that it is upregulated in both SAT and VAT conditionedmediummay
also explain the involvement of adipose tissues in tumour
aggressiveness.
Altogether, our results indicate that adipocytes secretome induce
malignant melanocytes aggressiveness. The synergic increase in
melanocyte survival, adhesion, motility, and plasticity allied to the
stimuli for cell–cell networks of vasculogenic mimicry patterns,
support the deleterious effects that adiposity partakes directly in
melanoma progression.
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